2025 Q4 -tulosraportti
Vain PDF
38 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenWhich dates will be important going forward? impossible to keep track with all these posts
·2 t sittenIF CIRCIO GOES DOWN, I GO DOWN TOO. 🧬♟️ Let me be honest about something. People call me a hype man. I get it. But here's the truth: I have nothing to sell you. No stock to pump. No exit strategy that requires you to buy. I'm in the same boat as you. And that boat is steered by people I actually trust. Erik Wiklund. 13 years in pharma. McKinsey. Algeta – sold to Bayer for 18 billion. He knows how these deals are done. He's been on the other side of the table. Thomas Hansen. CTO. Co-discovered circular RNA in 2011. He's not a salesman. He's the inventor. And Lubor Gaal. CFO. Former Head of Europe Search & Evaluation for Oncology at Bristol-Myers Squibb. He knows what Big Pharma pays for – and what they don't. This is not a team that sells dreams. This is a team that knows the buyers from the inside. They have lock-up. They can't sell before October. They have everything to lose if this goes wrong. And yet they are here. Building. Patenting. Presenting at ASGCT. Running in vivo with Big Pharma. I'm not hyping it. I trust the people running this company. And I'm in the same boat as them. We know what we own. ♟️🧱🍷
·1 t sittenMany words. Can we get a tip from you;, what will be the opening price on Tuesday?
·5 t sittenBearish analysis, short and simple: Let me lay it out directly: Orna vs. Circio – the real comparison: ORNA THERAPEUTICS: Employees: ~175 External funding: 322 million USD Founded: 2019 / 2020 Lead candidate: Clinically ready (ORN-252) Investors: BlackRock, Merck, Astellas CIRCIO HOLDING: Employees: 11 External funding: ~320 million NOK total Founded: 2010 Lead candidate: Pre-clinical (mouse models) Investors: Primarily retail on the Oslo Stock Exchange Orna had raised a total of 322 million dollars from investors including BlackRock, Merck and Astellas before the acquisition – i.e., from the very heaviest institutional players in the biotech world. Orna's lead candidate ORN-252 was moreover described as "clinical trial-ready" by Lilly at the time of acquisition. Circio, in comparison, has 11 employees, is in a pre-clinical phase with mouse models, and has raised approximately the same amount in KRONER as Orna raised in DOLLARS. The real point: Lilly paid 2.4 billion dollars for a company with 175 employees, massive dollar-muscles on the books, strategic partners like Merck and a clinically ready candidate. The market is now trying to transfer this premium valuation directly to Circio – a company that is a small fraction in terms of size, and which is at least 3–5 years behind in real development. It's not analysis. It's sentiment contagion. And sentiment-based price increases always reverse.8 ääntä 2 päivää 18 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
·3 t sitten · MuokattuErik Wiklund himself says that Circio is 12 to 24 months behind Orna, so that's no news. How much capital has been raised doesn't have to mean anything. If Circio now gets the warrant issue fully subscribed in June, they will have raised almost USD 100 mill. in total. That's not bad for a company that has probably gone under the radar of such as BlackRock and the others until now, but they do after all have an agreement with a large pharmaceutical company.
·9 t sittenHad Claude analyze Circio scenarios towards 2028 – here is the result: The figures below are calculated with a fully diluted share count of ~305 million shares, i.e., if all warrants are exercised. In practice, probably not all will be exercised, which means that the actual share count will be lower and the price targets correspondingly higher. The figures are therefore to be regarded as a conservative starting point. Here are my five scenarios ranked by probability: Scenario 1 – The gradual path (most likely) 2026 is the building year. Disease model data in heart and eye are delivered as planned in 2H 2026. CNS update from the big pharma collaboration is positive. A new license or collaboration agreement is announced – not an acquisition, but paying partnerships that commercially validate the platform. Candidate nomination is delivered early 2027 as promised. Primate data from the eye in 1H 2027 are strong. This triggers acquisition interest from one or more players, and a deal is announced during 2027 in the range of 1-2 billion dollars. In the event of an acquisition in the range of 1-2 billion dollars, this corresponds to a price of roughly 52-69 NOK per share – an increase of 460% to 645% from today's price of ~9 NOK Scenario 2 – The early acquisition (possible but not likely) An AAV specialist or mid-size pharma decides to act before candidate nomination – either because competition to own the circVec technology intensifies, or because the disease model data in 2H 2026 are so strong that they won't wait. Acquisition occurs in late 2026 or early 2027 at a price reflecting a pre-clinical stage – probably in the range of 800 million to 1.2 billion dollars. Lower than scenario 1, but faster. In the event of an acquisition in the range of 800 million to 1.2 billion dollars, this corresponds to a price of roughly 28-42 NOK per share – an increase of 200% to 350% from today's price. Lower than scenario 1, but significantly faster realized. Scenario 3 – The license model (interesting alternative) Circio chooses not to be acquired, but instead builds a license-based business model where multiple AAV companies pay to use circVec in their programs. This is in line with what Analyst Group described and what the CEO implies with the “software for gene therapy”-metaphor. The company remains independent into 2028 and builds revenues from agreements. The price rises gradually but without the explosive re-rating an acquisition would have provided. For you as an investor, this is the least attractive scenario in the short term, but potentially the most value-creating in the long term. Without a single exit event, the price development is gradual and dependent on revenue streams from license agreements. A realistic price target in 2027-2028 could be 20-35 NOK – an increase of 115% to 280% from today's price, but without the explosive re-rating an acquisition would be able to provide (continues below)·2 t sittenI forwarded the question. Got this as an answer: Scenario 6 with a share price of 200-350 NOK would correspond to a market value of 60-100 billion NOK – i.e., 3-4 times what Lilly paid for Orna, which is the largest acquisition in the sector to date. It is not impossible in theory, but it is not a scenario I can substantiate with actual comparative transactions. The scenarios are deliberately built on what the market has actually paid for similar technology – not on what one hopes for. SunsetSilver's point is relevant – over 2 billion dollars is absolutely not impossible, but then we are talking about a scenario where Circio has delivered clinical data and is in a bidding round between several major players. It could become a reality in 2027-2028 if everything goes according to plan, but it is too speculative to set a concrete price target now.
·1 t sittenYes, the problem with that is just a lack of nuance. As far as I have understood, there is no basis for direct comparison between CircVec technology and the technology that, for example, Orna had. According to statements and other references here, Circios' technology is far superior, which does not seem to be part of Claude's sentiment. There is probably a difference in how far these companies were in the testing phases, but the comparisons also stop there. As far as I am aware.
·12 t sittenCan those of us who have the opportunity to buy these warrant shares reply to this post. Will you buy these shares at this level or do you need to see over 10+ before you choose to buy and take this risk? For my own part, I will never redeem these shares if the price is not at 11-12 + plus I don't dare to take that risk then by buying new shares then. What are your thoughts on this?·4 t sittenHow does one buy warrants?
·4 t sittenTicker CRNAS, on an AF account. Must complete a knowledge test to buy warrants if you haven't done it before. Place an order just as usual when you buy shares. Note that warrants can have greater fluctuations in value than the underlying share itself and that a warrant must be redeemed or sold within the deadline, otherwise it expires worthless. Do not invest more than you are willing to lose.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
38 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWhich dates will be important going forward? impossible to keep track with all these posts
- ·2 t sittenIF CIRCIO GOES DOWN, I GO DOWN TOO. 🧬♟️ Let me be honest about something. People call me a hype man. I get it. But here's the truth: I have nothing to sell you. No stock to pump. No exit strategy that requires you to buy. I'm in the same boat as you. And that boat is steered by people I actually trust. Erik Wiklund. 13 years in pharma. McKinsey. Algeta – sold to Bayer for 18 billion. He knows how these deals are done. He's been on the other side of the table. Thomas Hansen. CTO. Co-discovered circular RNA in 2011. He's not a salesman. He's the inventor. And Lubor Gaal. CFO. Former Head of Europe Search & Evaluation for Oncology at Bristol-Myers Squibb. He knows what Big Pharma pays for – and what they don't. This is not a team that sells dreams. This is a team that knows the buyers from the inside. They have lock-up. They can't sell before October. They have everything to lose if this goes wrong. And yet they are here. Building. Patenting. Presenting at ASGCT. Running in vivo with Big Pharma. I'm not hyping it. I trust the people running this company. And I'm in the same boat as them. We know what we own. ♟️🧱🍷·1 t sittenMany words. Can we get a tip from you;, what will be the opening price on Tuesday?
- ·5 t sittenBearish analysis, short and simple: Let me lay it out directly: Orna vs. Circio – the real comparison: ORNA THERAPEUTICS: Employees: ~175 External funding: 322 million USD Founded: 2019 / 2020 Lead candidate: Clinically ready (ORN-252) Investors: BlackRock, Merck, Astellas CIRCIO HOLDING: Employees: 11 External funding: ~320 million NOK total Founded: 2010 Lead candidate: Pre-clinical (mouse models) Investors: Primarily retail on the Oslo Stock Exchange Orna had raised a total of 322 million dollars from investors including BlackRock, Merck and Astellas before the acquisition – i.e., from the very heaviest institutional players in the biotech world. Orna's lead candidate ORN-252 was moreover described as "clinical trial-ready" by Lilly at the time of acquisition. Circio, in comparison, has 11 employees, is in a pre-clinical phase with mouse models, and has raised approximately the same amount in KRONER as Orna raised in DOLLARS. The real point: Lilly paid 2.4 billion dollars for a company with 175 employees, massive dollar-muscles on the books, strategic partners like Merck and a clinically ready candidate. The market is now trying to transfer this premium valuation directly to Circio – a company that is a small fraction in terms of size, and which is at least 3–5 years behind in real development. It's not analysis. It's sentiment contagion. And sentiment-based price increases always reverse.8 ääntä 2 päivää 18 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn·3 t sitten · MuokattuErik Wiklund himself says that Circio is 12 to 24 months behind Orna, so that's no news. How much capital has been raised doesn't have to mean anything. If Circio now gets the warrant issue fully subscribed in June, they will have raised almost USD 100 mill. in total. That's not bad for a company that has probably gone under the radar of such as BlackRock and the others until now, but they do after all have an agreement with a large pharmaceutical company.
- ·9 t sittenHad Claude analyze Circio scenarios towards 2028 – here is the result: The figures below are calculated with a fully diluted share count of ~305 million shares, i.e., if all warrants are exercised. In practice, probably not all will be exercised, which means that the actual share count will be lower and the price targets correspondingly higher. The figures are therefore to be regarded as a conservative starting point. Here are my five scenarios ranked by probability: Scenario 1 – The gradual path (most likely) 2026 is the building year. Disease model data in heart and eye are delivered as planned in 2H 2026. CNS update from the big pharma collaboration is positive. A new license or collaboration agreement is announced – not an acquisition, but paying partnerships that commercially validate the platform. Candidate nomination is delivered early 2027 as promised. Primate data from the eye in 1H 2027 are strong. This triggers acquisition interest from one or more players, and a deal is announced during 2027 in the range of 1-2 billion dollars. In the event of an acquisition in the range of 1-2 billion dollars, this corresponds to a price of roughly 52-69 NOK per share – an increase of 460% to 645% from today's price of ~9 NOK Scenario 2 – The early acquisition (possible but not likely) An AAV specialist or mid-size pharma decides to act before candidate nomination – either because competition to own the circVec technology intensifies, or because the disease model data in 2H 2026 are so strong that they won't wait. Acquisition occurs in late 2026 or early 2027 at a price reflecting a pre-clinical stage – probably in the range of 800 million to 1.2 billion dollars. Lower than scenario 1, but faster. In the event of an acquisition in the range of 800 million to 1.2 billion dollars, this corresponds to a price of roughly 28-42 NOK per share – an increase of 200% to 350% from today's price. Lower than scenario 1, but significantly faster realized. Scenario 3 – The license model (interesting alternative) Circio chooses not to be acquired, but instead builds a license-based business model where multiple AAV companies pay to use circVec in their programs. This is in line with what Analyst Group described and what the CEO implies with the “software for gene therapy”-metaphor. The company remains independent into 2028 and builds revenues from agreements. The price rises gradually but without the explosive re-rating an acquisition would have provided. For you as an investor, this is the least attractive scenario in the short term, but potentially the most value-creating in the long term. Without a single exit event, the price development is gradual and dependent on revenue streams from license agreements. A realistic price target in 2027-2028 could be 20-35 NOK – an increase of 115% to 280% from today's price, but without the explosive re-rating an acquisition would be able to provide (continues below)·2 t sittenI forwarded the question. Got this as an answer: Scenario 6 with a share price of 200-350 NOK would correspond to a market value of 60-100 billion NOK – i.e., 3-4 times what Lilly paid for Orna, which is the largest acquisition in the sector to date. It is not impossible in theory, but it is not a scenario I can substantiate with actual comparative transactions. The scenarios are deliberately built on what the market has actually paid for similar technology – not on what one hopes for. SunsetSilver's point is relevant – over 2 billion dollars is absolutely not impossible, but then we are talking about a scenario where Circio has delivered clinical data and is in a bidding round between several major players. It could become a reality in 2027-2028 if everything goes according to plan, but it is too speculative to set a concrete price target now.·1 t sittenYes, the problem with that is just a lack of nuance. As far as I have understood, there is no basis for direct comparison between CircVec technology and the technology that, for example, Orna had. According to statements and other references here, Circios' technology is far superior, which does not seem to be part of Claude's sentiment. There is probably a difference in how far these companies were in the testing phases, but the comparisons also stop there. As far as I am aware.
- ·12 t sittenCan those of us who have the opportunity to buy these warrant shares reply to this post. Will you buy these shares at this level or do you need to see over 10+ before you choose to buy and take this risk? For my own part, I will never redeem these shares if the price is not at 11-12 + plus I don't dare to take that risk then by buying new shares then. What are your thoughts on this?·4 t sittenHow does one buy warrants?·4 t sittenTicker CRNAS, on an AF account. Must complete a knowledge test to buy warrants if you haven't done it before. Place an order just as usual when you buy shares. Note that warrants can have greater fluctuations in value than the underlying share itself and that a warrant must be redeemed or sold within the deadline, otherwise it expires worthless. Do not invest more than you are willing to lose.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
38 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWhich dates will be important going forward? impossible to keep track with all these posts
- ·2 t sittenIF CIRCIO GOES DOWN, I GO DOWN TOO. 🧬♟️ Let me be honest about something. People call me a hype man. I get it. But here's the truth: I have nothing to sell you. No stock to pump. No exit strategy that requires you to buy. I'm in the same boat as you. And that boat is steered by people I actually trust. Erik Wiklund. 13 years in pharma. McKinsey. Algeta – sold to Bayer for 18 billion. He knows how these deals are done. He's been on the other side of the table. Thomas Hansen. CTO. Co-discovered circular RNA in 2011. He's not a salesman. He's the inventor. And Lubor Gaal. CFO. Former Head of Europe Search & Evaluation for Oncology at Bristol-Myers Squibb. He knows what Big Pharma pays for – and what they don't. This is not a team that sells dreams. This is a team that knows the buyers from the inside. They have lock-up. They can't sell before October. They have everything to lose if this goes wrong. And yet they are here. Building. Patenting. Presenting at ASGCT. Running in vivo with Big Pharma. I'm not hyping it. I trust the people running this company. And I'm in the same boat as them. We know what we own. ♟️🧱🍷·1 t sittenMany words. Can we get a tip from you;, what will be the opening price on Tuesday?
- ·5 t sittenBearish analysis, short and simple: Let me lay it out directly: Orna vs. Circio – the real comparison: ORNA THERAPEUTICS: Employees: ~175 External funding: 322 million USD Founded: 2019 / 2020 Lead candidate: Clinically ready (ORN-252) Investors: BlackRock, Merck, Astellas CIRCIO HOLDING: Employees: 11 External funding: ~320 million NOK total Founded: 2010 Lead candidate: Pre-clinical (mouse models) Investors: Primarily retail on the Oslo Stock Exchange Orna had raised a total of 322 million dollars from investors including BlackRock, Merck and Astellas before the acquisition – i.e., from the very heaviest institutional players in the biotech world. Orna's lead candidate ORN-252 was moreover described as "clinical trial-ready" by Lilly at the time of acquisition. Circio, in comparison, has 11 employees, is in a pre-clinical phase with mouse models, and has raised approximately the same amount in KRONER as Orna raised in DOLLARS. The real point: Lilly paid 2.4 billion dollars for a company with 175 employees, massive dollar-muscles on the books, strategic partners like Merck and a clinically ready candidate. The market is now trying to transfer this premium valuation directly to Circio – a company that is a small fraction in terms of size, and which is at least 3–5 years behind in real development. It's not analysis. It's sentiment contagion. And sentiment-based price increases always reverse.8 ääntä 2 päivää 18 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn·3 t sitten · MuokattuErik Wiklund himself says that Circio is 12 to 24 months behind Orna, so that's no news. How much capital has been raised doesn't have to mean anything. If Circio now gets the warrant issue fully subscribed in June, they will have raised almost USD 100 mill. in total. That's not bad for a company that has probably gone under the radar of such as BlackRock and the others until now, but they do after all have an agreement with a large pharmaceutical company.
- ·9 t sittenHad Claude analyze Circio scenarios towards 2028 – here is the result: The figures below are calculated with a fully diluted share count of ~305 million shares, i.e., if all warrants are exercised. In practice, probably not all will be exercised, which means that the actual share count will be lower and the price targets correspondingly higher. The figures are therefore to be regarded as a conservative starting point. Here are my five scenarios ranked by probability: Scenario 1 – The gradual path (most likely) 2026 is the building year. Disease model data in heart and eye are delivered as planned in 2H 2026. CNS update from the big pharma collaboration is positive. A new license or collaboration agreement is announced – not an acquisition, but paying partnerships that commercially validate the platform. Candidate nomination is delivered early 2027 as promised. Primate data from the eye in 1H 2027 are strong. This triggers acquisition interest from one or more players, and a deal is announced during 2027 in the range of 1-2 billion dollars. In the event of an acquisition in the range of 1-2 billion dollars, this corresponds to a price of roughly 52-69 NOK per share – an increase of 460% to 645% from today's price of ~9 NOK Scenario 2 – The early acquisition (possible but not likely) An AAV specialist or mid-size pharma decides to act before candidate nomination – either because competition to own the circVec technology intensifies, or because the disease model data in 2H 2026 are so strong that they won't wait. Acquisition occurs in late 2026 or early 2027 at a price reflecting a pre-clinical stage – probably in the range of 800 million to 1.2 billion dollars. Lower than scenario 1, but faster. In the event of an acquisition in the range of 800 million to 1.2 billion dollars, this corresponds to a price of roughly 28-42 NOK per share – an increase of 200% to 350% from today's price. Lower than scenario 1, but significantly faster realized. Scenario 3 – The license model (interesting alternative) Circio chooses not to be acquired, but instead builds a license-based business model where multiple AAV companies pay to use circVec in their programs. This is in line with what Analyst Group described and what the CEO implies with the “software for gene therapy”-metaphor. The company remains independent into 2028 and builds revenues from agreements. The price rises gradually but without the explosive re-rating an acquisition would have provided. For you as an investor, this is the least attractive scenario in the short term, but potentially the most value-creating in the long term. Without a single exit event, the price development is gradual and dependent on revenue streams from license agreements. A realistic price target in 2027-2028 could be 20-35 NOK – an increase of 115% to 280% from today's price, but without the explosive re-rating an acquisition would be able to provide (continues below)·2 t sittenI forwarded the question. Got this as an answer: Scenario 6 with a share price of 200-350 NOK would correspond to a market value of 60-100 billion NOK – i.e., 3-4 times what Lilly paid for Orna, which is the largest acquisition in the sector to date. It is not impossible in theory, but it is not a scenario I can substantiate with actual comparative transactions. The scenarios are deliberately built on what the market has actually paid for similar technology – not on what one hopes for. SunsetSilver's point is relevant – over 2 billion dollars is absolutely not impossible, but then we are talking about a scenario where Circio has delivered clinical data and is in a bidding round between several major players. It could become a reality in 2027-2028 if everything goes according to plan, but it is too speculative to set a concrete price target now.·1 t sittenYes, the problem with that is just a lack of nuance. As far as I have understood, there is no basis for direct comparison between CircVec technology and the technology that, for example, Orna had. According to statements and other references here, Circios' technology is far superior, which does not seem to be part of Claude's sentiment. There is probably a difference in how far these companies were in the testing phases, but the comparisons also stop there. As far as I am aware.
- ·12 t sittenCan those of us who have the opportunity to buy these warrant shares reply to this post. Will you buy these shares at this level or do you need to see over 10+ before you choose to buy and take this risk? For my own part, I will never redeem these shares if the price is not at 11-12 + plus I don't dare to take that risk then by buying new shares then. What are your thoughts on this?·4 t sittenHow does one buy warrants?·4 t sittenTicker CRNAS, on an AF account. Must complete a knowledge test to buy warrants if you haven't done it before. Place an order just as usual when you buy shares. Note that warrants can have greater fluctuations in value than the underlying share itself and that a warrant must be redeemed or sold within the deadline, otherwise it expires worthless. Do not invest more than you are willing to lose.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt